Gazyva’s GALLIUM Could Be ‘Practice-Changing’ For Follicular Lymphoma
Executive Summary
Genentech’s next-generation anti-CD20 antibody Gazyva bested the Roche subsidiary’s original CD20-targeting therapy Rituxan in first-line follicular lymphoma – a result in the Phase III GALLIUM study that one oncologist viewed as “practice-changing.”
You may also be interested in...
Gazyva, Imfinzi Launched Following Japan Listing, Entyvio In The Wings
Japan has granted reimbursement prices to two anticancer antibodies and other products as it supports the availability of new, higher priced therapies in areas of high medical need, including through early access, while Takeda’s Entyvio is also set for launch.
Celgene Eases Angst Over Otezla, Sets The Stage For Growth
Celgene reported second quarter sales growth for key assets in its commercial portfolio, including a recovery for Otezla, and prepared investors for a deluge of data in the second half of 2017.
No Hat Trick For Roche's Gazyva In Lymphoma
Roche's Gazyva/Gazyvaro missed its primary endpoint in a Phase III study in first-line diffuse large B-cell lymphoma, failing to score a treble in lymphoma indications for the product, which the company is relying on to replace revenues from the increasingly biosimilared rituximab. The failure has also brought to investors' minds the larger uncertainty over Perjeta's future in breast cancer in the APHINITY study.